inistered with reduced doses of atazanavir and ritonavir
↑ atazanavir (↑ AUC, ↑ Cmax, ↑ Cmin) Atazanavir plasma concentrations achieved with atazanavir 300 mg q.d and ritonavir 100 mg q.d. are higher than those achieved with atazanavir 400 mg q.d. See the complete prescribing information for Reyataz® (atazanavir) for details on co-administration of atazanavir 300 mg q.d, with ritonavir 100 mg q.d.
HIV Protease Inhibitor:
darunavir When co-administered with reduced doses of ritonavir
↑ darunavir (↑ AUC, ↑ Cmax, ↑ Cmin) See the complete prescribing information for Prezista® (darunavir) for details on co-administration of darunavir 600 mg b.i.d. with ritonavir 100 mg b.i.d. or darunavir 800 mg q.d. with ritonavir 100 mg q.d.
HIV Protease Inhibitor:
fosamprenavir When co-administered with reduced doses of ritonavir
↑ amprenavir (↑ AUC, ↑ Cmax, ↑ Cmin) See the complete prescribing information for Lexiva® (fosamprenavir) for details on co-administration of fosamprenavir 700 mg b.i.d. with ritonavir 100 mg b.i.d., fosamprenavir 1400 mg q.d. with ritonavir 200 mg q.d. or fosamprenavir 1400 mg q.d. with ritonavir 100 mg q.d.
HIV Protease Inhibitor:
indinavir When co-administered with reduced doses of indinavir and ritonavir
↑ indinavir (↔AUC, ↓ Cmax, ↑ Cmin) Alterations in concentrations are noted when reduced doses of indinavir are co-administered with NORVIR.
Appropriate doses for this combination, with respect to efficacy and safety, have not been established.
HIV Protease Inhibitor:
saquinavir When co-administered with reduced doses of ritonavir
↑ saquinavir
(↑ AUC, ↑ Cmax, ↑Cmin) See the complete prescribing information for Invirase® (saquinavir) for details on co-administration of saquinavir 1000 mg b.i.d. with ritonavir 100 mg b.i.d.
Saquinavir/ritonavir should not be given together with rifampin, due to the risk of severe hepatotoxicity (presenting as increased hepatic transaminases) if the three drugs are given together.
HIV Protease Inhibitor:
tipranavir When co-administered with reduced doses of ritonavir
↑ tipranavir (↑ AUC, ↑ Cmax, ↑ Cmin) See the complete prescribing information for Aptivus® (tipranavir) for details on co-administration of tipranavir 500 mg b.i.d. with ritonavir 200 mg b.i.d. There have been reports of clinical hepatitis and hepatic decompensation including some fatalities. All patients should be followed closely with clinical and laboratory monitoring, especially those with chronic hepatitis B or C co-infection, as these patients have an increased risk of hepatotoxicity. Liver function tests should be performed prior to initiating therapy with tipranavir/ritonavir, and frequently throughout the duration of treatment.
Non-Nucleoside Reverse Transcriptase Inhibitor:
delavirdine ↑ ritonavir (↑AUC, ↑Cmax, ↑ Cmin) Appropriate doses of this combination with respect to safety and efficacy have not been established.
HIV CCR5 – antagonist: maraviroc ↑ maraviroc Concurrent administration of maraviroc with ritonavir will increase plasma levels of maraviroc. For specific dosage adjustment recommendations, please refer to the complete prescribing information for Selzentry® (maraviroc).
Other Agents
Analgesics, Narcotic:
tramadol, propoxyp |
